Vital Signs - Continued Opportunities in Diabetes Drug Delivery


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on January 26, 2009, provides a strategic overview of opportunities in drug delivery for the treatment of diabetes. Additionally, a company spotlight is provided for NanoBio Corporation, a company focused on the development and commercialization of topical and vaccine products utilizing its NanoStat technology platform. Reimbursement and regulatory news from the FDA is also provided for the week of January 12, 2009.

Table of Contents

Vital Signs - Continued Opportunities in Diabetes Drug DeliveryVital Signs: 26 January 2008This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.